Senecavirus a immunogenic compositions and methods thereof
OwnerArun V. Iyer, Abby Rae Patterson +4inventors
InventorsArun V. Iyer, Abby Rae Patterson, Joseph Gilbert Victoria, Eric Martin Vaughn, Luis Alejandro Hernandez, Jennifer L. English
Life of this patent
Estimating the term…
Abstract
The present invention relates to killed/inactivated and/or recombinant Senecavirus A immunogenic compositions and vaccines, and methods of preventing or treating animals in need of with such an immunogenic compositions and vaccines.
Claims19
A nucleic acid of a chemically inactivated virus comprising a polynucleotide, a complement of the polynucleotide, or a DNA equivalent of the polynucleotide or the polynucleotide complement, wherein the polynucleotide:
- (i) comprises 99% sequence identity to SEQ ID NO:
- 1;
- (ii) comprises 95% sequence identity to SEQ ID NO:
- 2;
- and/or (iii) encodes a polypeptide having the amino acid sequence of SEQ ID NO:
- 3, wherein the chemically inactivated virus is chemically inactivated by treatment with a chemical inactivating agent which includes a compound selected from the group consisting of:
- binary ethylenimine (BED), formaldehyde, ethylenimine, acetylethylenimine and mixtures thereof.
A nucleic acid of a chemically inactivated Senecavirus A (SVA) comprising a polynucleotide, a complement of the polynucleotide, or a DNA equivalent of the polynucleotide or the polynucleotide complement, wherein the polynucleotide:
- (i) comprises 99% sequence identity to SEQ ID NO:
- 1;
- (ii) comprises 95% sequence identity to SEQ ID NO:
- 2;
- and/or (iii) encodes a polypeptide having the amino acid sequence of SEQ ID NO:
- 3, wherein the chemically inactivated SVA is chemically inactivated by treatment with a chemical inactivating agent which includes a compound selected from the group consisting of:
- binary ethylenimine (BED), formaldehyde, ethylenimine, acetylethylenimine and mixtures thereof.
A vector comprising a nucleic acid of a recombinant or chemically inactivated virus comprising a polynucleotide, a complement of the polynucleotide, or a DNA equivalent of the polynucleotide or the polynucleotide complement, wherein the polynucleotide:
- (i) comprises 99% sequence identity to SEQ ID NO:
- 1;
- (ii) comprises 95% sequence identity to SEQ ID NO:
- 2;
- and/or (iii) encodes a polypeptide having the amino acid sequence of SEQ ID NO:
- 3.
A polypeptide of a chemically inactivated virus comprising an amino acid sequence that:
- (i) is encoded by a polynucleotide comprising 99% sequence identity to SEQ ID NO:
- 1 and/or 95% sequence identity to SEQ ID NO:2;
- (ii) has the amino acid sequence of SEQ ID NO:
- 3;
- (iii) corresponds to a P1-2A-P3 polypeptide and is encoded by a polynucleotide comprising 90% sequence identity to SEQ ID NO:
- 18, 20, 22, 24, 32, and/or 33;
- and/or (iv) has at least 90% sequence identity to SEQ ID NO:
- 19, 21, 23, 25, 27, and/or 29, wherein the chemically inactivated virus is chemically inactivated by treatment with a chemical inactivating agent which includes a compound selected from the group consisting of:
- binary ethylenimine (BED), formaldehyde, ethylenimine, acetylethylenimine and mixtures thereof.
A vaccine comprising a nucleic acid of a chemically inactivated virus comprising a polynucleotide, a complement of the polynucleotide, or a DNA equivalent of the polynucleotide or the polynucleotide complement, wherein the polynucleotide:
- (i) comprises 99% sequence identity to SEQ ID NO:
- 1;
- (ii) comprises 95% sequence identity to SEQ ID NO:
- 2;
- and/or (iii) encodes a polypeptide having the amino acid sequence of SEQ ID NO:
- 3 and a pharmaceutically acceptable carrier, excipient, and/or adjuvant, wherein the chemically inactivated virus is chemically inactivated by treatment with a chemical inactivating agent which includes a compound selected from the group consisting of:
- binary ethylenimine (BED), formaldehyde, ethylenimine, acetylethylenimine and mixtures thereof.
Dependencies are inferred from the claim text.